Targeting multidrug resistance in cancer

[1]  A. Townsend,et al.  Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux , 2006, Molecular Pharmacology.

[2]  J. Wijnholds,et al.  Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. , 2006, Journal of hepatology.

[3]  B. Norman.  Cyclohexyl‐Linked Tricyclic Isoxazoles are Potent and Selective Modulators of the Multidrug Resistance Protein (MRP1). , 2006 .

[4]  B. Norman,et al.  Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1). , 2005, Bioorganic & medicinal chemistry letters.

[5]  J. Verweij,et al.  Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. , 2005, Pharmacogenomics.

[6]  P. Sonneveld,et al.  The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. , 2005, Blood.

[7]  J. Beijnen,et al.  MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid , 2005, International journal of cancer.

[8]  Shufeng Zhou,et al.  Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins , 2005, Pharmaceutical Research.

[9]  A. Klein-Szanto,et al.  Analysis of the In Vivo Functions of Mrp3 , 2005, Molecular Pharmacology.

[10]  D. Piwnica-Worms,et al.  In vivo RNA Interference–Mediated Ablation of MDR1 P-Glycoprotein , 2005, Clinical Cancer Research.

[11]  H. McLeod,et al.  Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar , 2005, British Journal of Cancer.

[12]  G. Peters,et al.  The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. , 2005, Cancer research.

[13]  M. Gottesman,et al.  Transmembrane inhibitors of P-glycoprotein, an ABC transporter. , 2005, Journal of medicinal chemistry.

[14]  S. Cole,et al.  Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. , 2005, Toxicology and applied pharmacology.

[15]  P. Johnston,et al.  The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites , 2005, Molecular Cancer Therapeutics.

[16]  P. Pávek,et al.  Breast cancer resistance protein (BCRP/ABCG2). , 2005, The international journal of biochemistry & cell biology.

[17]  P. Wielinga,et al.  Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro , 2005, Molecular Cancer Therapeutics.

[18]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[19]  W. Greco,et al.  Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator , 2005, Clinical Cancer Research.

[20]  M. Raaijmakers,et al.  Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38− Cells in Acute Myeloid Leukemia , 2005, Clinical Cancer Research.

[21]  H. Samonigg,et al.  Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Lily Wu,et al.  Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection , 2005, Nature Medicine.

[23]  M. Blagosklonny.  How Cancer Could be Cured by 2015 , 2005, Cell cycle.

[24]  F. Russel,et al.  Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. , 2005, American journal of physiology. Renal physiology.

[25]  P. Kwan,et al.  Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy , 2005, Epilepsia.

[26]  B. Sarkadi,et al.  Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  Zhe-Sheng Chen,et al.  Transport of Bile Acids, Sulfated Steroids, Estradiol 17-β-d-Glucuronide, and Leukotriene C4 by Human Multidrug Resistance Protein 8 (ABCC11) , 2005, Molecular Pharmacology.

[28]  Gerhard F Ecker,et al.  Inhibitors of p-glycoprotein--lead identification and optimisation. , 2005, Mini reviews in medicinal chemistry.

[29]  A. Seelig,et al.  Inhibitors of multidrug efflux transporters: their membrane and protein interactions. , 2005, Mini reviews in medicinal chemistry.

[30]  W. Berger,et al.  Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications , 2005, Journal of Cancer Research and Clinical Oncology.

[31]  F. Martin,et al.  Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. , 2004, Seminars in oncology.

[32]  J. Robert.  MS-209 Schering. , 2004, Current opinion in investigational drugs.

[33]  M. Pallis,et al.  Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia , 2004, Leukemia.

[34]  D. Ross.  Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. , 2004, Best practice & research. Clinical haematology.

[35]  John N Weinstein,et al.  Analysis of ATP-Binding Cassette Transporter Expression in Drug-Selected Cell Lines by a Microarray Dedicated to Multidrug Resistances⃞ , 2004, Molecular Pharmacology.

[36]  Donald W. Miller,et al.  Plasma Membrane Localization of Multidrug Resistance-Associated Protein Homologs in Brain Capillary Endothelial Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[37]  M. Caligiuri,et al.  Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Mahadevan,et al.  Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. , 2004, Blood.

[39]  P. Sonneveld,et al.  Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. , 2004, Leukemia research.

[40]  P. Wielinga,et al.  Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy , 2004, Molecular and Cellular Biology.

[41]  H. Kusuhara,et al.  Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[42]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[43]  Dong Xu,et al.  Strategies for inhibition of MDR1 gene expression. , 2004, Molecular pharmacology.

[44]  A. di Pietro,et al.  Verapamil and Its Derivative Trigger Apoptosis through Glutathione Extrusion by Multidrug Resistance Protein MRP1 , 2004, Cancer Research.

[45]  Zhe-Sheng Chen,et al.  Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10) , 2004, Cancer Research.

[46]  B. Kroesen,et al.  MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells , 2004, International journal of cancer.

[47]  L. Benet,et al.  Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.

[48]  H. Fain,et al.  Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. , 2004, Molecular pharmaceutics.

[49]  S. Cole,et al.  Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). , 2004, Molecular pharmacology.

[50]  E. D. de Vries,et al.  Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation , 2004, British Journal of Cancer.

[51]  Kim L. R. Brouwer,et al.  The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.

[52]  R. Bendayan,et al.  Cellular localization and functional expression of P‐glycoprotein in rat astrocyte cultures , 2004, Journal of neurochemistry.

[53]  R. Advani,et al.  Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  C. Slapak,et al.  Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters. , 2004, Biochemical pharmacology.

[55]  L. Pendyala,et al.  VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein , 2004, Clinical Cancer Research.

[56]  C. Nicolau,et al.  Inhibition of multidrug resistance by immunisation with synthetic P-glycoprotein-derived peptides. , 2004, European journal of cancer.

[57]  Z. Sauna,et al.  The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). , 2004, Molecular pharmacology.

[58]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[59]  S. Cole,et al.  The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. , 2004, Current drug metabolism.

[60]  Lee Yong Lim,et al.  Herbal Modulation of P‐Glycoprotein , 2004, Drug metabolism reviews.

[61]  W. Löscher,et al.  Brain Access and Anticonvulsant Efficacy of Carbamazepine, Lamotrigine, and Felbamate in ABCC2/MRP2‐Deficient TR− Rats , 2003, Epilepsia.

[62]  P. Seeman,et al.  Blockade of G Protein-Coupled Receptors and the Dopamine Transporter by a Transmembrane Domain Peptide: Novel Strategy for Functional Inhibition of Membrane Proteins in Vivo , 2003, Journal of Pharmacology and Experimental Therapeutics.

[63]  K. Scotto.  Transcriptional regulation of ABC drug transporters , 2003, Oncogene.

[64]  I. Goldman,et al.  Resistance to antifolates , 2003, Oncogene.

[65]  G. Kruh,et al.  The MRP family of drug efflux pumps , 2003, Oncogene.

[66]  J. Robert,et al.  Multidrug resistance reversal agents. , 2003, Journal of medicinal chemistry.

[67]  T. Fojo,et al.  The role of ABC transporters in clinical practice. , 2003, The oncologist.

[68]  H. Kusuhara,et al.  Involvement of Multidrug Resistance Associated Protein 1 (Mrp1) in the Efflux Transport of 17β Estradiol-D-17β-Glucuronide (E217βG) Across the Blood-Brain Barrier , 2003, Pharmaceutical Research.

[69]  C. Sibley,et al.  Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. , 2003, American journal of physiology. Cell physiology.

[70]  B. Abbott.  ABCG2 (BCRP) expression in normal and malignant hematopoietic cells , 2003, Hematological oncology.

[71]  E. Solary,et al.  Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. , 2003, Blood.

[72]  Zhe-Sheng Chen,et al.  MRP8, ATP-binding Cassette C11 (ABCC11), Is a Cyclic Nucleotide Efflux Pump and a Resistance Factor for Fluoropyrimidines 2′,3′-Dideoxycytidine and 9′-(2′-Phosphonylmethoxyethyl)adenine* , 2003, Journal of Biological Chemistry.

[73]  T. Roskams,et al.  Expression and regulation of ABC transporter genes during liver regeneration , 2018 .

[74]  D. Keppler,et al.  Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane , 2003, Hepatology.

[75]  W. Löscher,et al.  Multidrug Resistance Protein MRP2 Contributes to Blood-Brain Barrier Function and Restricts Antiepileptic Drug Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[76]  K. Faber,et al.  ATP binding cassette transporter gene expression in rat liver progenitor cells , 2003, Gut.

[77]  B. Smith,et al.  Response to ‘comparison of “sequential” versus “standard” chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (aml): results of the uk medical research council aml‐r trial’ , 2003, British journal of haematology.

[78]  D. Schadendorf,et al.  Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. , 2003, The Journal of investigative dermatology.

[79]  D. Dormont,et al.  Atp Binding Cassette Multidrug Transporters Limit the Anti-HIV Activity of Zidovudine and Indinavir in Infected Human Macrophages , 2003, Antiviral therapy.

[80]  J. Wijnholds,et al.  Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. , 2003, Molecular pharmacology.

[81]  L. Bain,et al.  The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. , 2003, Toxicology letters.

[82]  O. van Tellingen,et al.  Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. , 2003, Cancer research.

[83]  Bruce Goldman,et al.  Multidrug resistance: can new drugs help chemotherapy score against cancer? , 2003, Journal of the National Cancer Institute.

[84]  T. Fojo,et al.  Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  D. D. de Alwis,et al.  Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. , 2003, Advanced drug delivery reviews.

[86]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[87]  M. Yamazaki,et al.  Clinical Relevance of P-Glycoprotein in Drug Therapy , 2003, Drug metabolism reviews.

[88]  B. Jégou,et al.  Multidrug Resistance Genes and P-Glycoprotein in the Testis of the Rat, Mouse, Guinea Pig, and Human1 , 2002, Biology of reproduction.

[89]  T. Hagve,et al.  The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice , 2002, Leukemia.

[90]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[91]  G. Knipp,et al.  Direct Evidence that Saquinavir Is Transported by Multidrug Resistance-Associated Protein (MRP1) and Canalicular Multispecific Organic Anion Transporter (MRP2) , 2002, Antimicrobial Agents and Chemotherapy.

[92]  Zhe-Sheng Chen,et al.  Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). , 2002, Cancer research.

[93]  Fei Li,et al.  Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. , 2002, Cancer research.

[94]  Dong Xu,et al.  Selective Inhibition of P-glycoprotein Expression in Multidrug-Resistant Tumor Cells by a Designed Transcriptional Regulator , 2002, Journal of Pharmacology and Experimental Therapeutics.

[95]  M. Caligiuri,et al.  Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. , 2002, Blood.

[96]  G. Kéri,et al.  Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. , 2002, Biochimica et biophysica acta.

[97]  A. Guo,et al.  Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[98]  E. Ezan,et al.  A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. , 2002, Analytical biochemistry.

[99]  M. Kuwano,et al.  Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. , 2002, Cancer research.

[100]  D. Postma,et al.  Multidrug resistance related molecules in human and murine lung. , 2002, Journal of clinical pathology.

[101]  M. Liscovitch,et al.  Cancer multidrug resistance: a review of recent drug discovery research. , 2002, IDrugs : the investigational drugs journal.

[102]  M. Kool,et al.  Tissue Distribution and Induction of Human Multidrug Resistant Protein 3 , 2002, Laboratory Investigation.

[103]  D. Quinn,et al.  The preferential induction of apoptosis in multidrug-resistant KB cells by 5-fluorouracil. , 2002, Cancer letters.

[104]  J. Beijnen,et al.  Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)* , 2001, The Journal of Biological Chemistry.

[105]  H. Gerhartz,et al.  Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914) , 2001, British journal of haematology.

[106]  M. Mayberg,et al.  Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy , 2001, Epilepsia.

[107]  J. Doroshow,et al.  Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.

[108]  R. O. Oude Elferink,et al.  Role of MRP2 and GSH in intrahepatic cycling of toxins. , 2001, Toxicology.

[109]  P. A. Rea,et al.  Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. , 2001, Cancer research.

[110]  C. B. Roth,et al.  Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. , 2001, Science.

[111]  Zhe-Sheng Chen,et al.  Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. , 2001, The Journal of biological chemistry.

[112]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[113]  K. Itoh,et al.  Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. , 2001, Cancer research.

[114]  L. Tartaglia,et al.  A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. , 2001, Cancer research.

[115]  Jie Liu,et al.  Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. , 2001, Molecular pharmacology.

[116]  T. Litman,et al.  Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. , 2001, Biochemical and biophysical research communications.

[117]  M. Blagosklonny.  Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells , 2001, Leukemia.

[118]  A. Burnett,et al.  Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial , 2001, British journal of haematology.

[119]  S. Cole,et al.  Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[121]  A. V. Van Gennip,et al.  Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. , 2001, Carcinogenesis.

[122]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[123]  K. Tew,et al.  Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). , 2001, Cancer research.

[124]  J. Hochman,et al.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. , 2001, The Journal of pharmacology and experimental therapeutics.

[125]  L. Doyle,et al.  Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. , 2001, Biochemical and biophysical research communications.

[126]  G. Szakács,et al.  Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia , 2001, British journal of haematology.

[127]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[128]  F. Sturtz,et al.  Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  P Bevan,et al.  Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[130]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[131]  P. Meier,et al.  Expression of members of the multidrug resistance protein family in human term placenta. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[132]  M. Kuo,et al.  BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. , 2000, Biochemical pharmacology.

[133]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[134]  J. Verweij,et al.  Development of Multidrug-Resistance Convertors: Sense or Nonsense? , 2000, Investigational New Drugs.

[135]  G. Szakács,et al.  MDR3 P-glycoprotein, a Phosphatidylcholine Translocase, Transports Several Cytotoxic Drugs and Directly Interacts with Drugs as Judged by Interference with Nucleotide Trapping* , 2000, The Journal of Biological Chemistry.

[136]  R. Juliano,et al.  Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinatorial libraries. , 2000, Molecular pharmacology.

[137]  M. Kool,et al.  Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport , 2000, British Journal of Cancer.

[138]  D. Clarke,et al.  Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. , 2000, Journal of the National Cancer Institute.

[139]  B. Vastag.  Almost serendipity: alcoholism drug reverses drug resistance in vitro. , 2000, Journal of the National Cancer Institute.

[140]  M. Vore,et al.  Expression and localization of multidrug resistant protein mrp2 in rat small intestine. , 2000, The Journal of pharmacology and experimental therapeutics.

[141]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[142]  S. Terry,et al.  Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum , 2000, Nature Genetics.

[143]  J. Verweij,et al.  The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[144]  R. Evers,et al.  Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. , 2000, Molecular pharmacology.

[145]  P. Meier,et al.  Transport function and hepatocellular localization of mrp6 in rat liver. , 2000, Molecular pharmacology.

[146]  M. Baccarani,et al.  P‐glycoprotein (PGP), lung resistance‐related protein (LRP) and multidrug resistance‐associated protein (MRP) expression in acute promyelocytic leukaemia , 2000, British journal of haematology.

[147]  I. Pastan,et al.  Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice , 2000, Gene Therapy.

[148]  D. Hipfner,et al.  Structural, mechanistic and clinical aspects of MRP1. , 1999, Biochimica et biophysica acta.

[149]  N. Tarasova,et al.  Inhibition of G-protein-coupled Receptor Function by Disruption of Transmembrane Domain Interactions* , 1999, The Journal of Biological Chemistry.

[150]  T. Uchiumi,et al.  Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.

[151]  T. Litman,et al.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. , 1999, Cancer letters.

[152]  J. Schellens,et al.  Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[153]  M. Burt,et al.  Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. , 1999, Clinical Cancer Research.

[154]  C. Higgins,et al.  The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein , 1999, British journal of pharmacology.

[155]  J. Schuetz,et al.  MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs , 1999, Nature Medicine.

[156]  A. Monks,et al.  Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. , 1999, Biochemical pharmacology.

[157]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[158]  A. Giuliano,et al.  Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug‐resistant cancer cells , 1999, Cancer.

[159]  G. Peters,et al.  MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[160]  G. Peters,et al.  Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. , 1999, Cancer research.

[161]  K. Peng,et al.  Tissue and Cell Distribution of the Multidrug Resistance-Associated Protein (MRP) in Mouse Intestine and Kidney , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[162]  D. Keppler,et al.  Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. , 1999, Molecular pharmacology.

[163]  N. Russell,et al.  Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG , 1999, Leukemia.

[164]  D. Keppler,et al.  Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane , 1999, Hepatology.

[165]  A. Sartorelli,et al.  Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[166]  P. Jansen,et al.  ATP‐ and glutathione‐dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1 , 1999, British journal of pharmacology.

[167]  Y. Sugiyama,et al.  Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. , 1999, The Journal of pharmacology and experimental therapeutics.

[168]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[169]  D. Quinn,et al.  2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. , 1998, British Journal of Cancer.

[170]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[171]  G. Szakács,et al.  Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain* , 1998, The Journal of Biological Chemistry.

[172]  Y. Sugiyama,et al.  Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. , 1998, Cancer research.

[173]  R. Arceci,et al.  Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  Richard J. Thompson,et al.  A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis , 1998, Nature Genetics.

[175]  V. Ling,et al.  Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. , 1998, Cancer research.

[176]  Caillot,et al.  Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study , 1998, British journal of haematology.

[177]  P. Meier,et al.  The Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver* , 1998, The Journal of Biological Chemistry.

[178]  D. Bell,et al.  Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. , 1998, Cancer research.

[179]  I. Pastan,et al.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.

[180]  E. Bruera,et al.  Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. , 1998, British Journal of Cancer.

[181]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[182]  T. Uchiumi,et al.  A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. , 1997, Cancer research.

[183]  J. Robert,et al.  Measuring multidrug resistance expression in human malignancies: elaboration of consensus recommendations. , 1997, Seminars in hematology.

[184]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[185]  B. Trock,et al.  Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. , 1997, Journal of the National Cancer Institute.

[186]  T. Grogan,et al.  Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins , 1997, Leukemia.

[187]  A. Schinkel,et al.  The physiological function of drug-transporting P-glycoproteins. , 1997, Seminars in cancer biology.

[188]  J. Bentley,et al.  The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation. , 1997, Cancer letters.

[189]  Y. Sugiyama,et al.  Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[190]  H. Tapiero,et al.  Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. , 1997, Biochemistry.

[191]  U. Germann,et al.  Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. , 1997, Anti-cancer drugs.

[192]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[193]  Piet Borst,et al.  MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein Specifically Translocates Phosphatidylcholine , 1996, Cell.

[194]  E. Solary,et al.  Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. , 1996, Blood.

[195]  V. Alakhov,et al.  Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. , 1996, Cancer research.

[196]  M. Relling.  Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? , 1996, Therapeutic drug monitoring.

[197]  S. Hegewisch‐Becker.  MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. , 1996, Leukemia.

[198]  B. Stewart,et al.  Involvement of MDR1 P‐glycoprotein in multifactorial resistance to methotrexate , 1996, International journal of cancer.

[199]  P. Bosma,et al.  Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.

[200]  D. Quinn,et al.  Gain and loss of hypersensitivity to resistance modifiers in multidrug resistant Chinese hamster ovary cells. , 1995, Cancer letters.

[201]  K. Cowan,et al.  Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. , 1995, Cancer research.

[202]  F. Baas,et al.  Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[203]  V. Ling,et al.  Identification of a sister gene to P-glycoprotein. , 1995, Cancer research.

[204]  J. Crowley,et al.  A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study , 1995, Cancer.

[205]  D. Kerr,et al.  Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[206]  P. Gros,et al.  Phosphatidylcholine translocase: A physiological role for the mdr2 gene , 1994, Cell.

[207]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[208]  D. Keppler,et al.  Differential inhibition by cyclosporins of primary‐active ATP‐dependent transporters in the hepatocyte canalicular membrane , 1993, FEBS letters.

[209]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[210]  R. Milroy,et al.  A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. , 1993, British Journal of Cancer.

[211]  P. Corris,et al.  Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. , 1993, British Journal of Cancer.

[212]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[213]  Y. Tanigawara,et al.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). , 1992, The Journal of pharmacology and experimental therapeutics.

[214]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[215]  I. Roninson,et al.  Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[216]  M. Dietel,et al.  Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. , 1992, Biochemical pharmacology.

[217]  R. Boucher,et al.  Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. , 1992, The Journal of biological chemistry.

[218]  P. Twentyman.  Cyclosporins as drug resistance modifiers. , 1992, Biochemical pharmacology.

[219]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[220]  M. Gottesman,et al.  The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. , 1991, Cancer research.

[221]  T. Tsuruo,et al.  Monoclonal Anti‐P‐glycoprotein Antibody‐dependent Killing of Multidrug‐resistant Tumor Cells by Human Mononuclear Cells , 1990, Japanese journal of cancer research : Gann.

[222]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[223]  M C Willingham,et al.  Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[224]  M. Center,et al.  Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. , 1988, Cancer research.

[225]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[226]  I. Pastan,et al.  A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[227]  S. Mirski,et al.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. , 1987, Cancer research.

[228]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[229]  J. Endicott,et al.  Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance , 1986, Nature.

[230]  D. Housman,et al.  Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins , 1986, Cell.

[231]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[232]  I. Pastan,et al.  Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. , 1986, The Journal of biological chemistry.

[233]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[234]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[235]  K. Danø.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. , 1973, Biochimica et biophysica acta.

[236]  S. Cole,et al.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line , 2008, Cancer Chemotherapy and Pharmacology.

[237]  L. Naesens,et al.  Role of MRP4 and MRP5 in biology and chemotherapy , 2008, AAPS PharmSci.

[238]  T. Dale,et al.  The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk , 2005, Nature Medicine.

[239]  N. Russell,et al.  P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. , 2005, Experimental hematology.

[240]  H. Grunicke,et al.  Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine , 2005, Journal of Cancer Research and Clinical Oncology.

[241]  M. Pallis,et al.  Flow cytometric measurement of functional and phenotypic P-glycoprotein. , 2005, Methods in molecular medicine.

[242]  P. Herdewijn,et al.  Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. , 2004, Nucleic acids research.

[243]  Dong Xu,et al.  Strategies for Inhibition of MDR 1 Gene Expression , 2004 .

[244]  B. Han,et al.  Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. , 2004, Current medicinal chemistry. Anti-cancer agents.

[245]  Xin Wang,et al.  Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. , 2003, Molecular pharmacology.

[246]  A. Dantzig,et al.  Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979 , 2003, International journal of cancer.

[247]  T. Fojo,et al.  Increased 99 mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor , XR 9576 , 2003 .

[248]  Kellen Ja.  The reversal of multidrug resistance: an update , 2003 .

[249]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[250]  T. Litman,et al.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[251]  D. Keppler,et al.  Hepatic Secretion of Conjugated Drugs and Endogenous Substances , 2000, Seminars in liver disease.

[252]  L. Mayer,et al.  Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug‐resistant solid tumors by co‐administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin , 2000, International journal of cancer.

[253]  L. Doyle,et al.  Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. , 2000, Cancer research.

[254]  R. Johnstone,et al.  Multiple physiological functions for multidrug transporter P-glycoprotein? , 2000, Trends in biochemical sciences.

[255]  R. Kim,et al.  Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. , 2000, Molecular pharmacology.

[256]  Ronald,et al.  MRP 3 , an organic anion transporter able to transport anti-cancer drugs ( multidrug resistance y methotrexate y etoposide ) , 1999 .

[257]  M. D. Boer,et al.  Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents , 1999, Leukemia.

[258]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[259]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[260]  E. Solary,et al.  Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. , 1999, Advances in experimental medicine and biology.

[261]  G. Szakács,et al.  Diagnostics of multidrug resistance in cancer. , 1998, Pathology oncology research : POR.

[262]  N. Neamati,et al.  Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines , 1997, Leukemia.

[263]  D. Scheinberg,et al.  Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. , 1996, Leukemia.

[264]  R. Arceci,et al.  P-glycoprotein mediates profound resistance to bisantrene. , 1994, Oncology research.

[265]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[266]  E. Vellenga,et al.  The value of the MDR 1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia ( AML ) , in relation to MDR 1 status at diagnosis , 2022 .